By Kejal Vyas BOGOTÁ -- Colombia's government will override Novartis's patent on a cancer medication by the end of May and open it up to generic manufacturers unless the Swiss pharmaceutical giant accepts a price cut, the country's health minister ... 4 Traders, 1 week ago
/PRNewswire/ -- Novartis will highlight the strength of its oncology research programs at the upcoming 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), being held June 3-7 in Chicago. Data will demonstrate advances across ...TickerTech.com, 1 week ago
MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer
Novartis International AG / . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. Independent Data Monitoring Committee recommends stopping the trial early as it met ...Bloomberg, 1 week ago MONALEESA-2 trial of Novartis LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer PharmaVOICE, 1 week ago
Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex
/PRNewswire/ -- Novartis today announced results from a Phase III study showing Afinitor®* (everolimus), when used as an adjunctive therapy, significantly reduced treatment-resistant seizures associated with tuberous sclerosis complex (TSC) ...TickerTech.com, 1 month ago
on your WebpageAdd Widget >Get your members hooked!